Yuhan Corp. posted a fourth-quarter operating profit of 26.1 billion won, swinging to profit and largely meeting market expectations, driven by strong pharmaceuticals sales and milestone payments from China.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q4Results #Pharmaceuticals #MilestonePayments #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=105008
Yuhan Corp. Swings to Profit in Q4 With Operating Income of 26.1 Billion Won, Largely in Line With Expectations
Yuhan Corp. posted a fourth-quarter operating profit of 26.1 billion won, swinging to profit and largely meeting market expectations, driven by strong pharmaceuticals sales and milestone payments from China.
Celltrion has signed a licensing deal with Trioor, securing exclusive rights to develop up to six targets using the TROCAD platform, with total payments potentially reaching 522 billion won ($400 million).
#YonhapInfomax #Celltrion #Trioor #TROCAD #LicenseAgreement #MilestonePayments #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=91533
Celltrion Signs Platform Technology Implementation and License Agreement with Trioor
Celltrion has signed a licensing deal with Trioor, securing exclusive rights to develop up to six targets using the TROCAD platform, with total payments potentially reaching 522 billion won ($400 million).
Yuhan Corp. Reports 55.7% Drop in Q3 Operating Profit—Impact of Milestone Absence (Comprehensive)
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit due to the absence of Leclaza milestone payments, with results missing market expectations.
Chong Kun Dang Reports Q2 Operating Profit of 22.1 Billion Won, Down 21.9%—'R&D Expenses Rise'
Chong Kun Dang Pharmaceutical saw Q2 operating profit fall 21.9% to 22.1 billion won as higher R&D costs offset revenue gains from milestone payments.
Yonhap Infomax News